Form 8-K

CVS HEALTH CORPORATION

Date: August 22, 2019

/s/ Eva C. Boratto

Eva C. Boratto

Executive Vice President and Chief Financial Officer

0001193125-19-226402.txt : 20190822 0001193125-19-226402.hdr.sgml : 20190822 20190822081002 ACCESSION NUMBER: 0001193125-19-226402 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20190821 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190822 DATE AS OF CHANGE: 20190822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CVS HEALTH Corp CENTRAL INDEX KEY: 0000064803 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] IRS NUMBER: 050494040 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-01011 FILM NUMBER: 191044224 BUSINESS ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 BUSINESS PHONE: 4017651500 MAIL ADDRESS: STREET 1: ONE CVS DR. CITY: WOONSOCKET STATE: RI ZIP: 02895 FORMER COMPANY: FORMER CONFORMED NAME: CVS CAREMARK CORP DATE OF NAME CHANGE: 20070509 FORMER COMPANY: FORMER CONFORMED NAME: CVS/CAREMARK CORP DATE OF NAME CHANGE: 20070322 FORMER COMPANY: FORMER CONFORMED NAME: CVS CORP DATE OF NAME CHANGE: 19970128 8-K 1 d13436d8k.htm FORM 8-K Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 21, 2019

CVS HEALTH CORPORATION

(Exact name of registrant as specified in its charter)


Delaware	001-01011	05-0494040
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

One CVS Drive, Woonsocket, Rhode Island		02895
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (401) 765-1500

Former name or former address, if changed since last report: N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, par value $0.01 per share

CVS

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Section 8 - Other Events

Item 8.01. Other Events

On August 21, 2019 and August 22, 2019, CVS Health Corporation, a Delaware corporation (the “Company”), issued press releases announcing the (A) pricing and (B) early results and election of early settlement, respectively, of its cash tender offers (the “Maximum Tender Offers”) for (1) up to $723,339,000 aggregate principal amount (the “2020 Notes Maximum Tender Offer Amount”) of its Floating Rate Notes due 2020 and its 2.800% Senior Notes due 2020 (collectively, the “2020 Maximum Tender Offer Notes”) validly tendered and accepted for purchase and (2) up to $961,648,000 aggregate principal amount (the “2021 Notes Maximum Tender Offer Amount”) of its 3.350% Senior Notes due 2021, its Floating Rate Notes due 2021 and its 2.125% Senior Notes due 2021 (collectively, the “2021 Maximum Tender Offer Notes” and, together with the 2020 Maximum Tender Offer Notes, the “Maximum Tender Offer Notes”) validly tendered and accepted for purchase in connection with the Company’s previously announced cash tender offers commenced on August 8, 2019.

Because the Company expects to accept for purchase, subject to proration, the 2020 Notes Maximum Tender Offer Amount of 2020 Maximum Tender Offer Notes and, subject to proration, the 2021 Notes Maximum Tender Offer Amount of 2021 Maximum Tender Offer Notes, no additional Maximum Tender Offer Notes will be purchased pursuant to the Maximum Tender Offers after August 23, 2019, the early settlement date for such Maximum Tender Offer Notes validly tendered and accepted for purchase by the Company.

Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2, which are incorporated by reference herein.

Section 9 - Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

The exhibit to this Current Report on Form 8-K is as follows:

INDEX TO EXHIBITS


	99.1			Press Release of CVS Health Corporation dated August 21, 2019

	99.2			Press Release of CVS Health Corporation dated August 22, 2019

	104			Cover Page Interactive File (the cover page tags are embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EX-99.1 2 d13436dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

LOGO


Investor	Valerie Haertel	Media	T.J. Crawford
Contact:	Senior Vice President	Contact:	Vice President
	Investor Relations		External Affairs
	(401) 770-4050		(212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Pricing of Maximum Tender Offers

WOONSOCKET, RI, August 21, 2019 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the applicable Reference Yields and Total Consideration (each as summarized in the tables below) to be paid in connection with the previously announced cash tender offers (the “Maximum Tender Offers,” and each a “Maximum Tender Offer”) for (1) up to $723,339,000 aggregate principal amount (the “2020 Notes Maximum Tender Offer Amount”) of its Floating Rate Notes due 2020 (the “2020 Floating Rate Notes”) and its 2.800% Senior Notes due 2020 (collectively, the “2020 Maximum Tender Offer Notes”) and (2) up to $961,648,000 aggregate principal amount (the “2021 Notes Maximum Tender Offer Amount”, and together with the 2020 Notes Maximum Tender Offer Amount, the “Maximum Tender Offer Amounts”) of its 3.350% Senior Notes due 2021, its Floating Rate Notes due 2021 (the “2021 Floating Rate Notes”, and together with the 2020 Floating Rate Notes, the “Floating Rate Notes”) and its 2.125% Senior Notes due 2021 (collectively, the “2021 Maximum Tender Offer Notes” and together with the 2020 Maximum Tender Offer Notes, the “Maximum Tender Offer Notes”).

The applicable Reference Yield for the Maximum Tender Offer Notes other than the Floating Rate Notes and the Total Consideration for the Maximum Tender Offer Notes are summarized in the tables below:

2020 Maximum Tender Offer Notes:

Title of Notes

CUSIP
Number

Original
Issuer

Principal
Amount
Outstanding

Acceptance
Priority
Level⁽¹⁾

UST
Reference
Security

Bloomberg
Reference
Page

Fixed
Spread
(bps)

Early
Tender
Payment⁽²⁾

Reference
Yield

Total
Consideration

Floating Rate Notes due 2020

126650DB3

CVS Health
Corporation

1,000,000,000

N/A

$30

N/A

$1,005.00

2.800% Senior Notes due 2020

126650CJ7

CVS Health
Corporation

2,750,000,000

1.500%

UST due
06/15/2020

PX3

$30

1.800%

$1,006.51

2021 Maximum Tender Offer Notes:

Title of Notes

CUSIP
Number

Original
Issuer

Principal
Amount
Outstanding

Acceptance
Priority
Level⁽¹⁾

UST
Reference
Security

Bloomberg
Reference
Page

Fixed
Spread
(bps)

Early
Tender
Payment⁽²⁾

Reference
Yield

Total
Consideration

3.350% Senior Notes due 2021

126650DC1

CVS Health
Corporation

3,000,000,000

1.750%

UST due

07/31/2021

PX1

$30

1.532

$1,022.24

Floating Rate Notes due 2021

126650DD9

CVS Health
Corporation

1,000,000,000

N/A

$30

N/A

$1,006.50

2.125% Senior Notes due 2021

126650CT5

CVS Health
Corporation

1,750,000,000

1.750%

UST due

07/31/2021

PX1

$30

1.532

$1,004.02

(1)

Subject to each of the Maximum Tender Offer Amounts and proration, the principal amount of each series of Maximum Tender Offer Notes that is purchased in each of the Maximum Tender Offers will be determined in accordance with the applicable acceptance priority level (in numerical priority order) specified in this column.

(2)	Per $1,000 principal amount of Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

The Maximum Tender Offers are being made upon the terms and subject to the conditions set forth in the Offer to Purchase dated August 8, 2019 (as amended or supplemented from time to time, the “Offer to Purchase”), which sets forth a more detailed description of the Maximum Tender Offers. Copies of the Offer to Purchase are available at www.dfking.com/cvs. The Maximum Tender Offers are open to all registered holders (individually, a “Holder” and collectively, the “Holders”) of the Maximum Tender Offer Notes.

The Total Consideration for each $1,000 principal amount of the Maximum Tender Offer Notes other than the Floating Rate Notes was determined in the manner described in the Offer to Purchase by reference to the applicable fixed spread set forth in the tables above plus the yield to maturity of the applicable UST Reference Security set forth in the tables above on the bid-side price of such UST Reference Security as of 10:00 a.m., New York City time, on August 21, 2019.

Maximum Tender Offer Notes validly tendered and not validly withdrawn at or prior to 5:00 p.m., New York City time, on August 21, 2019 (the “Early Tender Date”) will be eligible to receive the applicable Total Consideration for the Maximum Tender Offer Notes, which includes the Early Tender Payment. The Maximum Tender Offer Notes validly tendered after the Early Tender Date but at or prior to 11:59 p.m., New York City time, on September 5, 2019 (the “Maximum Tender Offer Expiration Date”) will be eligible to receive the applicable tender offer consideration, namely the applicable Total Consideration minus the Early Tender Payment specified in the tables above.

The settlement date for the Maximum Tender Offer Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase is expected to be August 23, 2019, the second business day after the Early Tender Date (the “Early Settlement Date”). The settlement date for the Maximum Tender Offer Notes validly tendered after the Early Tender Date but at or prior to the Maximum Tender Offer Expiration Date and accepted for purchase is expected to be September 9, the second business day after the Maximum Tender Offer Expiration Date (the “Final Settlement Date” and together with the Early Settlement Date, each a “Settlement Date”), if either or both of the Maximum Tender Offer Amounts of applicable Maximum Tender Offer Notes is not purchased on such Early Settlement Date.

In addition to the Total Consideration for the Maximum Tender Offer Notes, Holders of the Maximum Tender Offer Notes accepted for purchase on the Early Settlement Date will receive accrued and unpaid interest (“Accrued Interest”) on those Maximum Tender Offer Notes from the last interest payment date with respect to those Maximum Tender Offer Notes to, but not including, the Early Settlement Date.

Holders who tender their Maximum Tender Offer Notes at or prior to 5:00 p.m., New York City time, on August 21, 2019 (such date and time, as it may be extended, the “Maximum Tender Offer Withdrawal Deadline”) may withdraw such tendered Maximum Tender Offer Notes at any time at or prior to the Maximum Tender Offer Withdrawal Deadline. Following the Maximum Tender Offer Withdrawal Deadline, Holders who have tendered their Maximum Tender Offer Notes (whether before, on or after the Maximum Tender Offer Withdrawal Deadline) may not withdraw such Maximum Tender Offer Notes unless CVS Health is required to extend withdrawal rights under applicable law.

CVS Health expressly reserves the right, in its sole discretion, subject to applicable law, to terminate the Maximum Tender Offers at any time prior to the Maximum Tender Offer Expiration Date. The Maximum Tender Offers are not conditioned on any minimum principal amount of Maximum Tender Offer Notes being tendered but the Maximum Tender Offers are subject to a financing condition and certain other general conditions as described in the Offer to Purchase.

CVS Health has retained Barclays Capital Inc. and Goldman Sachs & Co. LLC to act as Dealer Managers for the Tender Offers (as defined in the Offer to Purchase). D.F. King & Co., Inc. has been retained to act as the Tender and Information Agent for the Tender Offers. The Offer to Purchase may be accessed at the following link: http://www.dfking.com/cvs. Requests for assistance relating to the procedures for tendering Notes (as defined in the Offer to Purchase) may be directed to the Tender and Information Agent either by email at cvs@dfking.com, or by phone (212) 269-5550 (for banks and brokers only) or (866) 406-2283 (for all others toll free). Requests for assistance relating to the terms and conditions of the Tender Offers may be directed to Barclays Capital Inc. at (800) 438-3242 (toll free) or (212) 528-7581 (collect) or Goldman Sachs & Co. LLC at (800) 828-3182 (toll free) or (212) 902-2995 (collect). Beneficial owners may also contact their broker, dealer, commercial bank, trust company or other nominee for assistance.

This press release does not constitute an offer to sell or purchase, or a solicitation of an offer to sell or purchase, or the solicitation of tenders with respect to, the Notes. No offer, solicitation, purchase or sale will be made in any jurisdiction in which such an offer, solicitation, or sale would be unlawful. The Tender Offers are being made solely pursuant to the Offer to Purchase made available to Holders of the Notes. None of CVS Health, the Dealer Managers, Tender and Information Agent or the trustees with respect to the Notes, or any of their respective affiliates, is making any recommendation as to whether or not Holders should tender or refrain from tendering all or any portion of their Notes in response to the Tender Offers. Holders are urged to evaluate carefully all information in the Offer to Purchase, consult their own investment and tax advisers and make their own decisions whether to tender Notes in the Tender Offers, and, if so, the principal amount of Notes to tender.

About CVS Health

CVS Health is the nation’s premier health innovation company helping people on their path to better health. Whether in one of its pharmacies or through its health services and plans, CVS Health is pioneering a bold new approach to total health by making quality care more affordable, accessible, simple and seamless. CVS Health is community-based and locally focused, engaging consumers with the care they need when and where they need it. The Company has approximately 9,900 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 102 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year and expanding specialty pharmacy services. CVS Health also serves an estimated 38 million people through traditional, voluntary and consumer-directed health insurance products and related services, including rapidly expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. By their nature, all forward-looking statements involve risks and uncertainties. Actual results may differ materially from those contemplated by the forward-looking statements for a number of reasons as described in our Securities and Exchange Commission filings, including those set forth in the Risk Factors section and under the section entitled “Cautionary Statement Concerning Forward-Looking Statements” in our most recently filed Annual Report on Form 10-K and in our most recently filed Quarterly Report on Form 10-Q.

You are cautioned not to place undue reliance on CVS Health’s forward looking statements. These forward-looking statements are and will be based upon management’s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. CVS Health does not assume any duty to update or revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date.

EX-99.2 3 d13436dex992.htm EX-99.2 EX-99.2

Exhibit 99.2

LOGO


Investor	Valerie Haertel	Media	T.J. Crawford
Contact:	Senior Vice President	Contact:	Vice President
	Investor Relations		External Affairs
	(401) 770-4050		(212) 457-0583

FOR IMMEDIATE RELEASE

CVS Health Corporation Announces Early Results of Maximum Tender Offers and Election of Early Settlement

WOONSOCKET, RI, August 22, 2019 – CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today the early results of the previously announced cash tender offers (the “Maximum Tender Offers,” and each a “Maximum Tender Offer”) for (1) up to $723,339,000 aggregate principal amount (the “2020 Notes Maximum Tender Offer Amount”) of its Floating Rate Notes due 2020 (the “2020 Floating Rate Notes”) and its 2.800% Senior Notes due 2020 (the “2020 2.800% Notes” and, together with the 2020 Floating Rate Notes, the “2020 Maximum Tender Offer Notes”) and (2) up to $961,648,000 aggregate principal amount (the “2021 Notes Maximum Tender Offer Amount”, and together with the 2020 Notes Maximum Tender Offer Amount, the “Maximum Tender Offer Amounts”) of its 3.350% Senior Notes due 2021 (the “2021 3.350% Notes”), its Floating Rate Notes due 2021 (the “2021 Floating Rate Notes”, and together with the 2020 Floating Rate Notes, the “Floating Rate Notes”) and its 2.125% Senior Notes due 2021 (the “2021 2.125% Notes” and, together with the 2021 3.350% Notes and the 2021 Floating Rate Notes, the “2021 Maximum Tender Offer Notes”; the 2020 Maximum Tender Offer Notes and the 2021 Maximum Tender Offer Notes are referred to collectively as the “Maximum Tender Offer Notes”). The Maximum Tender Offer for the 2020 Maximum Tender Offer Notes is referred to as the “2020 Notes Maximum Tender Offer” and the Maximum Tender Offer for the 2021 Maximum Tender Offer Notes is referred to as “2021 Notes Maximum Tender Offer”.

As of 5:00 p.m., New York City time, on August 21, 2019 (the “Early Tender Date”), as reported by D.F. King & Co., Inc., the Tender and Information Agent for the Maximum Tender Offers, the principal amounts of the Maximum Tender Offer Notes listed in the tables below have been validly tendered and not validly withdrawn (except for series of Maximum Tender Offer Notes that are not expected to be accepted for purchase, as explained below). The Maximum Tender Offer Withdrawal Deadline of 5:00 p.m., New York City time, on August 21, 2019 has passed and, accordingly, Maximum Tender Offer Notes validly tendered in the Maximum Tender Offers may no longer be withdrawn. The Maximum Tender Offers were made pursuant to the terms and conditions set forth in the Offer to Purchase dated August 8, 2019 (as amended or supplemented from time to time, the “Offer to Purchase”).

CVS Health announced its election, with respect to the Maximum Tender Offer Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date, to accept for purchase and make payment for such Maximum Tender Offer Notes on August 23, 2019 (the “Early Settlement Date”), subject to the acceptance priority levels applicable to the relevant series as described in the Offer to Purchase and, in the case of the 2020 Floating Rate Notes for the 2020 Notes Maximum Tender Offer, and in the case of the 2021 3.350% Notes for the 2021 Notes Maximum Tender Offer, to proration as described in the Offer to Purchase.

Because the aggregate principal amount of 2020 Maximum Tender Offer Notes validly tendered and accepted for purchase would exceed the 2020 Maximum Tender Offer Amount, CVS Health expects that it will accept validly tendered 2020 Floating Rate Notes on a prorated basis in accordance with the Offer to Purchase and none of the validly tendered 2020 2.800% Notes. Because the aggregate principal amount of 2021 Maximum Tender Offer Notes validly tendered and accepted for purchase would exceed the 2021 Maximum Tender Offer Amount, CVS Health expects that it will accept validly tendered 2021 3.350% Notes on a prorated basis in accordance with the Offer to Purchase and none of the validly tendered 2021 Floating Rate Notes or 2021 2.125% Notes.

Because CVS Health expects to accept for purchase, subject to proration, the 2020 Notes Maximum Tender Offer Amount of 2020 Maximum Tender Offer Notes and, subject to proration, the 2021 Notes Maximum Tender Offer Amount of 2021 Maximum Tender Offer Notes, no additional Maximum Tender Offer Notes will be purchased pursuant to the Maximum Tender Offers after the Early Settlement Date. As described in the Offer to Purchase, Maximum Tender Offer Notes tendered and not accepted for purchase will be promptly returned to the tendering Holder’s account.

Holders of all Maximum Tender Offer Notes validly tendered and not validly withdrawn at or prior to the Early Tender Date and accepted for purchase are eligible to receive the applicable Total Consideration set forth in the tables below, which includes the applicable Early Tender Payment of $30 per $1,000 principal amount of Maximum Tender Offer Notes tendered at or prior to the Early Tender Date. In addition to the applicable Total Consideration, Holders of Maximum Tender Offer Notes accepted for purchase will receive accrued and unpaid interest up to, but not including, the Early Settlement Date.

2020 Maximum Tender Offer Notes⁽¹⁾:

Title of Notes

CUSIP
Number

Original
Issuer

Acceptance
Priority
Level

Total
Consideration

Early
Tender
Payment⁽²⁾

Principal
Amount
Outstanding

Principal
Amount
Tendered

Principal
Amount
Accepted

Floating Rate Notes due 2020

126650DB3

CVS Health
Corporation

$1,005.00

$30

1,000,000,000

$803,664,000

723,339,000

⁽³⁾

2021 Maximum Tender Offer Notes⁽⁴⁾:

Title of Notes

CUSIP
Number

Original
Issuer

Acceptance
Priority
Level

Total
Consideration

Early
Tender
Payment⁽²⁾

Principal
Amount
Outstanding

Principal
Amount
Tendered

Principal
Amount
Accepted

3.350% Senior Notes due 2021

126650DC1

CVS Health
Corporation

$1,022.24

$30

3,000,000,000

2,059,365,000

961,622,000

⁽³⁾

(1)	Because the aggregate principal amount of 2021 Maximum Tender Offer Notes validly tendered and accepted for purchase would exceed the 2021 Maximum Tender Offer Amount, none of the validly tendered 2020 2.800% Notes are expected to be accepted for purchase.

(2)	Per $1,000 principal amount of Maximum Tender Offer Notes validly tendered at or prior to the Early Tender Date and accepted for purchase.

(3)	After application of proration factor.

(4)	Because the aggregate principal amount of 2021 Maximum Tender Offer Notes validly tendered and accepted for purchase would exceed the 2021 Maximum Tender Offer Amount, none of the validly tendered 2021 Floating Rate Notes or 2021 2.125% Notes are expected to be accepted for purchase.

About CVS Health

Forward-Looking Statements

EX-101.SCH 4 cvs-20190821.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 5 cvs-20190821_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 6 cvs-20190821_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g13436g0821133524443.jpg GRAPHIC begin 644 g13436g0821133524443.jpg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g13436g0821204430175.jpg GRAPHIC begin 644 g13436g0821204430175.jpg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end GRAPHIC 9 g13436g0822064808312.jpg GRAPHIC begin 644 g13436g0822064808312.jpg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end XML 10 d13436d8k_htm.xml IDEA: XBRL DOCUMENT 0000064803 2019-08-21 2019-08-21 CVS HEALTH Corp false 0000064803 8-K 2019-08-21 DE 001-01011 05-0494040 One CVS Drive Woonsocket RI 02895 (401) 765-1500 false false false false Common Stock, par value $0.01 per share CVS NYSE false XML 11 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	Aug. 21, 2019
Cover [Abstract]
Entity Registrant Name	CVS HEALTH Corp
Amendment Flag	false
Entity Central Index Key	0000064803
Document Type	8-K
Document Period End Date	Aug. 21, 2019
Entity Incorporation State Country Code	DE
Entity File Number	001-01011
Entity Tax Identification Number	05-0494040
Entity Address, Address Line One	One CVS Drive
Entity Address, City or Town	Woonsocket
Entity Address, State or Province	RI
Entity Address, Postal Zip Code	02895
City Area Code	(401)
Local Phone Number	765-1500
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.01 per share
Trading Symbol	CVS
Security Exchange Name	NYSE
Entity Emerging Growth Company	false

EXCEL 12 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( $!!%D\?(\\#P !," + 7W)E;',O+G)E;'.MDD^+ MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F' M.>RGGD7E2B.5^S3%":4A+,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C M-R."?S]PN -02P,$% @ 0$$63R?HAPZ" L0 ! !D;V-0&UL38Y-"\(P$$3_2NG=;BGH06) L$?!D_>0;FP@R8;-"OGYIH(? MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/ M-(X'P"J8%EQV^3O8:W7..7AKQ%/25V^9"CGIYFHQ*/B76_..7+8\#?NW_+"" MWTG] E!+ P04 " ! 019/ZZ!;XN\ K @ $0 &1O8U!R;W!S+V-O M&ULS9+/:L,P#(=?9?B>R$EI:4V:R\9.'0Q6V-C-V&IK%O_!UDCZ]G.R M-F5L#["CI9\_?0(U*@CE(SY''S"2P70WV,XEH<*6G8B" $CJA%:F,B=<;AY\ MM)+R,QXA2/4ACP@UYRNP2%)+DC "BS 36=MH)51$23Y>\%K-^/ 9NPFF%6"' M%ATEJ,H*6#M.#.>A:^ &&&&$T:;O NJ9.%7_Q$X=8)?DD,R&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T M$W-I=MNTF83M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY M\^XN8NB&B)3R> +]O6N[!3+UES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4? M,_@5RU2-9:,!$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA M5,+$P&IG/U9KQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M M&N#C\7@XMLO2BW A(5M>5 TR 6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T M1G*=D 4. #?$T4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2. MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$. M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07 M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL! M_]':-\*K^(+ .7\N?<^E[[GT/:'2MSAD M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W MF)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>( M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K> M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5 MYYN MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+ MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> , M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H: M,]6+K#F-"F]!U4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ M 5!+ P04 " ! 019/"ZJV$ MZ]O7!H(B[_I/P&9FQ_9XE"UZJ=YUQ;F)/AK1ZEU<&=-MDT2?*MXP_2([WMHO M%ZD:9NQ071/=*<[. ZD1"4W39=*PNHW+8I@[J+*0-R/JEA]4I&]-P]2_/1>R MW\4D?DR\U=?*N(FD+#IVY3^Y^=4=E!TEY(PR( MWS7O]=-[Y+9RE/+=#;Z==W'J5L0%/QE7@MG'G;]R(5PENXZ_4]%XUG3$Y_=' M]2_#YNUFCDSS5RG^U&=3[>)U')WYA=V$>9/]5SYM:!%'T^Z_\SL7%NY68C5. M4NCA-SK=M)'-5,4NI6$?X[-NAV<_?LD?-)Q )P+U",DH-*S\,S.L+)3L(S4> M?L> MZ!2G9R@]&^CY$SWSU@<1.2Z0HP(YH"\\ 8A8X@(+5& !Z"M/ "+6N, 2%5@" M^L83@ B2X@HK5&$%^<230" !G]>HQ!KR?:,12,#I#2JQ@7S?:@02\)JD>)Q2 M6,&W&\,$#">!T!)8P?<-0)3#(%[B.8D/MXW@F,,P7N0TP6> 64SSW%&8Z]V\Q@O$/+'EJIUR[^H.I M:]WJZ"B-[&V7/IB U[9#GD>"'XQ[G5EW]78)HX#([NI!4[F/KS\ M#U!+ P04 " ! 019/=!N/-T8" #L!0 % 'AL+W-H87)E9%-T&ULA51-;]I $#VGOV*$>F@EP&L*%"J"A( T*)2@@!JU50^+/=BKVKO. M[IK O^\8$E1Y<>.3[7GS9N;-Q\ 8"_LTD>:Z%EN;??$\$\28X*,\:D++KT.+^?VR<:QVJ.'7:&.LYH'] M7;:_T#]@) H$!5WP%!V6[RNXG8[FZUL8*YTY&5"VX3'CFX1'9>N6)\9A?(D[ M)B?-$RHOQ#W8SWZ]P M7?,]S$(J26Q%<$JD@JC38.U^F[59!=,H##4:4W]]@;F0"/?2*8-^03$,$RUV M53T]DXV++Z5AK9Z=H7U42AH5_$'[%LM)6Z)9:K43,G#"/LS>HE@J8VG(?HKL M8F]8J]?O."-_9*#-O>CRH&9,3 M^'\^*PQR74CCMS:P%C9Q;P4Q'E>"NEN'C&O8\21'>,^:S(>,B$W,M>.VUCPL M*EL=THURZJ*9J\QDN@]B+B.\>+D6/U95FS=-44=%R*]:/=NXD"+C\I\+Y-&9 M'_X%4$L#!!0 ( $!!%D^ZH3F*UP$ #(& - >&POC"@J"RL.?!U[2=MH'<3*?'=G^]2=/;T0?Q MX(.^-#/?3+[YGTP!07FA:9'M23PIY49M"8TQ-E1=88O2-W- (^E2L@%RYS M^LBE*)V8<[D2BF0TR0@_6L,)]$+*A<>);1Q 62Q0OR62_I/ M@=7KO2NDW 2F- )%9CDB./WDG3EY!G\)D<4^3]8K;!V?DO2>[A/FP1S'A13MK_Z_O,M_HI@MW7-HT:L&W5!2#D*B MT(O&3M0U1'GAA_GUM#P0>)S6/$HQ:#>S@7WOT3Q U!+ P04 " ! 019/%FTC?T,! \ M @ #P 'AL+W=O+N)!NRPH_(WD#+UW?M*(7>>K)W=CP[.UZT)-X%>*X-F[OD.[+^1$B@9]H&V:9U>Q49ZQ!/"+[(#3UC](9(J/Q1[+>0L9\$C!BQ1 M(WT7,MTU2-XBNUHCY3">0XAS_Y\87=-@!2M7]08L#3EZT'&Z#2UV00JK#!1R MI AE:_%HB=V(M1VDF!MWX='K>MB+.+&+6>'GR V_KB?)^.BVA@8MU&\$##. M(50;+^*1=*:W=Y-[#KO7^H&Q=_OJ5-*/&N/'+7\ 4$L#!!0 ( $!!%D__ MP"8(O0 (4" : >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'.MDD$* M@S 0 +\B>4!7;>FAJ*=>O+;]0-#5B)J$[);J[YMZ44&A!R$8LX'LQYT4,CQT>7S%1]_276<]>@C"MA[_)1/TU MP.K795]02P,$% @ 0$$63PN/V ,A 0 5P0 !, !;0V]N=&5N=%]4 M>7!E&ULM51-3\,P#/TK4Z]HS># 6V[ %>8!'\@)&X;-5^RO=']>]QN M0V(J8FC;)8GS[/=>$BOS]VT&FG3!1UH4#7-^4(I, T%3F3)$0:J$0;.$6*NL M3:MK4'>SV;TR*3)$GG+/42SG3U#IM>?)XVZ_IUX4.F?OC&:7HMI$>T0ZW1.6 M"'[(H<9ENI&$8O+<"0O)WJ(0E IU@L)Q81]+W>L&$)V%?UE+5>4,V&3604I* MR@C:4@/ P9?4: 3[QNABO?>[TL@O.@BQZKSZD5!>SP=O/8P;&)!+*K.T!8Q) M#PGPG;83UV MX=\@J6$Z[];_:'29RZ!=_,W(1TKM05\-_\GR"U!+ 0(4 Q0 ( $!!%D\? M(\\#P !," + " 0 !?D !D;V-0 M&UL4$L! A0#% @ 0$$63^N@6^+O *P( !$ M ( !F0$ &1O8U!R;W!S+V-O&UL4$L! A0#% @ 0$$6 M3YE&PO=V]R:W-H965T&UL4$L! A0#% @ 0$$6 M3W0;CS=& @ [ 4 !0 ( !R L 'AL+W-H87)E9%-T&UL4$L! A0#% @ 0$$63[JA.8K7 0 ,@8 T M ( !0 X 'AL+W-T>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ 0$$63__ )@B] A0( !H ( !LA$ 'AL+U]R96QS M+W=O XML 13 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 14 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.2 html 1 97 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d13436d8k.htm cvs-20190821.xsd cvs-20190821_lab.xml cvs-20190821_pre.xml d13436dex991.htm d13436dex992.htm g13436g0821133524443.jpg http://xbrl.sec.gov/dei/2019-01-31 true false JSON 18 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d13436d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d13436d8k.htm" ] }, "labelLink": { "local": [ "cvs-20190821_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "cvs-20190821_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "cvs-20190821.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 97, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cvs", "nsuri": "http://www.cvshealth.com/20190821", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d13436d8k.htm", "contextRef": "duration_2019-08-21_to_2019-08-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "body", "html" ], "baseRef": "d13436d8k.htm", "contextRef": "duration_2019-08-21_to_2019-08-21", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.cvshealth.com//20190821/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 19 0001193125-19-226402-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-19-226402-xbrl.zip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end